10/30
08:00 am
celu
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care
Low
Report
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care
10/14
08:45 am
celu
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
Medium
Report
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
9/24
09:42 am
celu
Michel Dard of BioCellgraft Wins Business Worldwide Magazines 2025 CEO Award [Yahoo! Finance]
Medium
Report
Michel Dard of BioCellgraft Wins Business Worldwide Magazines 2025 CEO Award [Yahoo! Finance]
9/9
11:21 am
celu
Celularity (NASDAQ:CELU) was upgraded by analysts at WBB Securities from a "hold" rating to a "buy" rating. They now have a $6.00 price target on the stock.
Low
Report
Celularity (NASDAQ:CELU) was upgraded by analysts at WBB Securities from a "hold" rating to a "buy" rating. They now have a $6.00 price target on the stock.